COLLEGEVILLE, Pennsylvania, September 20 /PRNewswire/ --

- European Committee Issues Negative Opinion on MYLOTARG(R) for Acute 
Myeloid Leukemia; Wyeth Plans to Appeal

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today
that it has received a positive opinion from the Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines Evaluation Agency
(EMEA) for the approval of TORISEL(TM) (temsirolimus) as a first-line therapy
for patients with advanced renal cell carcinoma (RCC) who have at least three
of six prognostic risk factors. The CHMP's opinion for TORISEL will now be
forwarded to the European Commission for final approval, anticipated in
November 2007.

"The CHMP's positive opinion underscores the importance of TORISEL, which
has been shown to extend median overall survival in patients with advanced
kidney cancer when compared with interferon-alpha," says Robert R. Ruffolo,
Ph.D., President, Wyeth Research. The expected European Commission approval
for TORISEL will be its second major approval. The United States Food and
Drug Administration granted TORISEL its first approval in May 2007.

TORISEL has an Orphan Medicinal Product designation in the European Union
for the treatment of renal cell carcinoma. About 85,700 new cases of kidney
cancer were diagnosed in Europe in 2002, according to estimates from the
International Agency for Research on Cancer, and renal cell carcinoma
accounts for about 85 percent of all kidney cancers.

The CHMP issued a negative opinion regarding the marketing authorization
for MYLOTARG(R) (gemtuzumab ozogamicin) for re-induction treatment of
CD33-positive acute myeloid leukemia (AML) adult patients in first relapse
who are not candidates for other intensive re-induction chemotherapy regimens
(e.g., high-dose ARA-C). Among reasons cited for its opinion, the CHMP said
the three main clinical studies for MYLOTARG only showed a modest activity,
since only a small proportion of the 277 patients enrolled achieved complete
remission (where leukemia cells are no longer detected in the blood and are
at very low levels in the bone marrow). In addition, the CHMP noted that
there was no available information comparing the efficacy of MYLOTARG to
other treatments. The CHMP also said it was difficult to judge the length of
remission and effect on survival. Wyeth plans to request a re-examination of
the negative opinion, in accordance with current European regulatory
legislation.

"We believe that MYLOTARG is an important drug treatment for acute
myeloid leukemia, and we will continue to work with the CHMP to address the
committee's concerns and pursue a way forward," Dr. Ruffolo says. About
27,000 cases of AML will be diagnosed in the United Kingdom, France, Germany,
Spain, Italy, the United States and Japan in 2008.

About TORISEL(TM) (temsirolimus)

TORISEL was approved by the U.S. Food and Drug Administration (FDA) in
May 2007 for the treatment of advanced RCC.

TORISEL specifically inhibits the mTOR (mammalian target of rapamycin)
kinase, an important regulator of cell proliferation, cell growth and cell
survival. Inhibition of mTOR in treated cancer cells blocked the translation
of genes that regulate the cell cycle. In in vitro studies using renal cancer
cell lines, TORISEL inhibited the activity of mTOR and resulted in reduced
levels of certain cell growth factors involved in the development of new
blood vessels, such as vascular endothelial growth factor.

TORISEL U.S. Important Safety Information

Hypersensitivity reactions manifested by symptoms, including, but not
limited to anaphylaxis, dyspnea, flushing, and chest pain have been observed
with TORISEL.

Serum glucose, serum cholesterol, and triglycerides should be tested
before and during treatment with TORISEL(TM) (temsirolimus).

The use of TORISEL is likely to result in hyperglycemia and hyperlipemia.
This may result in the need for an increase in the dose of, or initiation of,
insulin and/or oral hypoglycemic agent therapy and/or lipid-lowering agents,
respectively.

The use of TORISEL may result in immunosuppression. Patients should be
carefully observed for the occurrence of infections, including opportunistic
infections.

Cases of interstitial lung disease, some resulting in death, have
occurred. Some patients were asymptomatic and others presented with symptoms.
Some patients required discontinuation of TORISEL and/or treatment with
corticosteroids and/or antibiotics.

Cases of fatal bowel perforation occurred with TORISEL. These patients
presented with fever, abdominal pain, metabolic acidosis, bloody stools,
diarrhea, and/or acute abdomen.

Cases of rapidly progressive and sometimes fatal acute renal failure not
clearly related to disease progression occurred in patients who received
TORISEL.

Due to abnormal wound healing, use TORISEL with caution in the
perioperative period.

Patients with central nervous system tumors (primary CNS tumor or
metastases) and/or receiving anticoagulation therapy may be at an increased
risk of developing intracerebral bleeding (including fatal outcomes) while
receiving TORISEL(TM) (temsirolimus).

Live vaccinations and close contact with those who received live vaccines
should be avoided.

Patients and their partners should be advised to avoid pregnancy
throughout treatment and for 3 months after TORISEL therapy has stopped.

The most common (incidence greater than or equal to 30%) adverse
reactions observed with TORISEL are: rash (47%), asthenia (51%), mucositis
(41%), nausea (37%), edema (35%), and anorexia (32%). The most common
laboratory abnormalities (incidence greater than or equal to 30%) are anemia
(94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%),
elevated alkaline phosphatase (68%), elevated serum creatinine (57%),
lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated
AST (38%), and leukopenia (32%).

Most common grades 3/4 adverse events included asthenia (11%), dyspnea
(9%), hemoglobin decreased (20%), lymphocytes decreased (16%), glucose
increased (16%), phosphorus decreased (18%), and triglycerides increased
(44%).

Strong inducers of CYP3A4/5 (eg, dexamethasone, rifampin) and strong
inhibitors of CYP3A4 (eg, ketoconazole, atazanavir) may decrease and increase
concentrations of the major metabolite of TORISEL, respectively. If
alternatives cannot be used, dose modifications of TORISEL(TM) (temsirolimus)
are recommended.

St. John's Wort may decrease TORISEL plasma concentrations, and
grapefruit juice may increase plasma concentrations of the major metabolite
of TORISEL, and therefore both should be avoided.

The combination of TORISEL and sunitinib resulted in dose-limiting
toxicity.

Please see TORISEL full U.S. prescribing information at
http://www.TORISEL.com.

About MYLOTARG

MYLOTARG is indicated in the United States for the treatment of patients
with CD33-positive acute myeloid leukemia in first relapse who are 60 years
of age or older and who are not considered candidates for other cytotoxic
chemotherapy. The safety and efficacy of MYLOTARG in patients with poor
performance status and organ dysfunction has not been established.

The effectiveness of MYLOTARG is based on overall response rates. There
are no controlled trials demonstrating a clinical benefit, such as
improvement in disease-related symptoms or increased survival, compared to
any other treatment.

MYLOTARG U.S. Important Safety Information

WARNINGS: MYLOTARG should be administered under the supervision of
physicians experienced in the treatment of acute leukemia and in facilities
equipped to monitor and treat leukemia patients. There are no controlled
trials demonstrating efficacy and safety using MYLOTARG in combination with
other chemotherapeutic agents. Therefore, MYLOTARG should only be used as
single agent chemotherapy and not in combination chemotherapy regimens
outside clinical trials. Severe myelosuppression occurs when MYLOTARG is used
at recommended doses.

HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS, INFUSION REACTIONS,
PULMONARY EVENTS: MYLOTARG administration can result in severe
hypersensitivity reactions (including anaphylaxis), and other
infusion-related reactions which may include severe pulmonary events.
Infrequently, hypersensitivity reactions and pulmonary events have been
fatal. In most cases, infusion-related symptoms occurred during the infusion
or within 24 hours of administration of MYLOTARG and resolved. MYLOTARG
infusion should be interrupted for patients experiencing dyspnea or
clinically significant hypotension. Patients should be monitored until signs
and symptoms completely resolve. Discontinuation of MYLOTARG(R) (gemtuzumab
ozogamicin) treatment should be strongly considered for patients who develop
anaphylaxis, pulmonary edema, or acute respiratory distress syndrome. Since
patients with high peripheral blast counts may be at greater risk for
pulmonary events and tumor lysis syndrome, physicians should consider
leukoreduction with hydroxyurea or leukapheresis to reduce the peripheral
white count to below 30,000/microL prior to administration of MYLOTARG. (See
WARNINGS.)

HEPATOTOXICITY: Hepatotoxicity, including severe hepatic veno-occlusive
disease (VOD), has been reported in association with the use of MYLOTARG as a
single agent, as part of a combination chemotherapy regimen, and in patients
without a history of liver disease or hematopoietic stem-cell transplant
(HSCT). Patients who receive MYLOTARG either before or after HSCT, patients
with underlying hepatic disease or abnormal liver function, and patients
receiving MYLOTARG in combinations with other chemotherapy are at increased
risk for developing VOD, including severe VOD. Death from liver failure and
from VOD has been reported in patients who received MYLOTARG. Physicians
should monitor their patients carefully for symptoms of hepatotoxicity,
particularly VOD. These symptoms can include: rapid weight gain, right upper
quadrant pain, hepatomegaly, ascites, elevations in bilirubin and/or liver
enzymes. However, careful monitoring may not identify all patients at risk or
prevent the complications of hepatotoxicity. (See WARNINGS and ADVERSE
REACTIONS sections.)

MYLOTARG(R) (gemtuzumab ozogamicin) is contraindicated in patients with a
known hypersensitivity to gemtuzumab ozogamicin or any of its components and
in lactating mothers. MYLOTARG may cause fetal harm when administered to a
pregnant woman. The reported rate of Grade 3 or 4 thrombocytopenia,
neutropenia, anemia, and bleeding were 99%, 98%, 52%, and 13%, respectively.
Thirty percent of patients experienced severe infections, including sepsis
(17%) and pneumonia (8%).

The most common adverse events (greater than or equal to 20%) were fever
(82%), nausea (68%), chills (66%), vomiting (58%), thrombocytopenia (50%),
leukopenia (47%), headache (37%), asthenia (36%), abdominal pain (32%),
diarrhea (32%), epistaxis (28%), dyspnea (26%), hypokalemia (26%), sepsis
(26%), anorexia (25%), stomatitis (25%), liver function tests abnormal (24%),
constipation (23%), anemia (22%), local reaction (22%), herpes simplex (21%),
and hypotension (20%).

MYLOTARG can produce a postinfusion symptom complex of fever and chills,
and less commonly hypotension and dyspnea during the first 24 hours after
administration. Patients should receive diphenhydramine 50 mg po and
acetaminophen 650-1000 mg po 1 hour before MYLOTARG administration. Two
additional doses of acetaminophen 650-1000 mg po every 4 hours may be given.
Fever and chills were commonly reported despite premedication with
diphenhydramine and acetaminophen. Vital signs should be monitored during
infusion and for 4 hours following infusion. Methylprednisolone given prior
to MYLOTARG(R) (gemtuzumab ozogamicin) infusion may ameliorate
infusion-related symptoms.

Severe myelosuppression will occur in all patients given the recommended
dose of this agent. Careful hematologic monitoring is required. Systemic
infections should be treated.

Please see MYLOTARG full U.S. prescribing information at
http://www.Wyeth.com.

Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the
areas of women's health care, infectious disease, gastrointestinal health,
central nervous system, inflammation, transplantation, hemophilia, oncology,
vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and
health care products companies. It is a leader in the discovery, development,
manufacturing and marketing of pharmaceutical, vaccines, biotechnology
products and non-prescription medicines that improve the quality of life for
people worldwide. The Company's major divisions include Wyeth 
Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are
forward-looking statements based on current expectations of future events and
are subject to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such statements. These
risks and uncertainties include the inherent uncertainty of the timing and
success of, and expense associated with, research, development, regulatory
approval and commercialization of our products, including with respect to our
pipeline products; government cost-containment initiatives; restrictions on
third-party payments for our products; substantial competition in our
industry, including from branded and generic products; data generated on our
products; the importance of strong performance from our principal products
and our anticipated new product introductions; the highly regulated nature of
our business; product liability, intellectual property and other litigation
risks and environmental liabilities; uncertainty regarding our intellectual
property rights and those of others; difficulties associated with, and
regulatory compliance with respect to, manufacturing of our products; risks
associated with our strategic relationships; economic conditions including
interest and currency exchange rate fluctuations; changes in generally
accepted accounting principles; trade buying patterns; the impact of
legislation and regulatory compliance; risks and uncertainties associated
with global operations and sales; and other risks and uncertainties,
including those detailed from time to time in our periodic reports filed with
the Securities and Exchange Commission, including our current reports on Form
8-K, quarterly reports on Form 10-Q and annual report on Form 10-K,
particularly the discussion under the caption "Item 1A, Risk Factors." The
forward-looking statements in this press release are qualified by these risk
factors. We assume no obligation to publicly update any forward-looking
statements, whether as a result of new information, future developments or
otherwise.

Web site: http://www.wyeth.com
              http://www.TORISEL.com